Compound
← Compound
Official website →
AAgilent Technologies, INC.
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- A
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-10-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (…
IndustryMedical - Diagnostics & Research
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
30.74×
P/B
Price divided by book value
5.99×
EV/EBITDA
Enterprise value divided by operating cash generation
23.56×
EV/Revenue
Enterprise value divided by revenue
6.29×
What the company earns
ROE
Return on shareholders’ equity
20.5%
ROA
Return on all assets
10.3%
Gross margin
What remains after product costs
53.7%
Operating margin
What remains after operating the business
22.2%
Net margin
How much of each revenue unit becomes profit
19.5%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
0.54
Total debt
Sum of borrowings
$3.95B
Cash
Cash available to cover it
$1.76B
Current ratio
Short-term assets divided by short-term liabilities
2.05
Free cash flow
Cash left after investing
$439M
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
1.24
Revenue growth
Compared with the same period a year earlier
8.1%
Earnings growth
Compared with the same period a year earlier
7.7%
Dividend yield
Trailing 12-month distributions divided by price
0.6%
Market data provider figures for the latest published period. Informational, not investment advice.
What research firms say
Strong buy 1Buy 32Hold 7Sell 1· 41 firms
Published targetsrange 23% from lowest to highest
150.00median 173.50 USD185.00
Recent revisions
Wells FargoOverweight
JP MorganOverweight
Evercore ISI GroupOutperform
Research-firm survey compiled by StreetInsider, Benzinga, Pulse 2.0. This is not Compound analysis or investment advice — Compound does not issue price targets.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 6.85B | 6.83B | 6.51B | 6.95B |
| Custo dos produtos | -3.13B | -3.37B | -2.98B | -3.31B |
| Despesas com vendas e administrativas | -1.64B | -1.63B | -1.57B | -1.71B |
| Pesquisa e desenvolvimento | -467M |
News about A
Yahoo Finance · 2 days ago
Agilent (A) Wants Pathology Labs To Go Digital, 540 Slides At A Time
Follow A and get agent analysis of what is moving the stock.
Open Compound